ArQule to Report First Quarter 2013 Financial Results on May 8, 2013

  ArQule to Report First Quarter 2013 Financial Results on May 8, 2013

Business Wire

WOBURN, Mass. -- May 1, 2013

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial
results for the first quarter of 2013 on Wednesday, May 8, 2013 at 7:00 a.m.
Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern
Time that day to discuss these results.

                               
Conference Call and Webcast
Date:                               Wednesday, May 8, 2013
Time:                               9:00 a.m., Eastern Time
                                    
Conference Call Numbers
Domestic (toll free):               (877) 868-1831
International:                      (914) 495-8595
Webcast:                            www.arqule.com
                                    

A replay of the conference call will be available beginning two hours after
the completion of the call until the end of May 10, 2013 and can be accessed
by dialing toll-free 855-859-2056 and outside the U.S. 404-537-3406. The
confirmation code for replayed calls is 33189641.

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ
087, designed to inhibit fibroblast growth factor receptor (FGFR); ARQ 621,
designed to inhibit the Eg5 kinesin motor protein; and ARQ 736, designed to
inhibit the RAF kinases. ArQule’s current discovery efforts, which are based
on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the
identification of novel kinase inhibitors that are potent, selective and do
not compete with ATP (adenosine triphosphate) for binding to the kinase.

Contact:

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com
 
Press spacebar to pause and continue. Press esc to stop.